A U.S. ban on copycat versions of Novo Nordisk's Wegovy has begun to lift use of the weight loss drug, but the company will ...

Questions, critiques and discrepancies are hanging over the framework agreement, but investors seem to view it as a win all ...

Dr Reddy's Laboratories plans to launch a cheaper copycat version of Novo Nordisk's blockbuster weight-loss drug Wegovy in 87 ...

Novo Nordisk A/S (NYSE:NVO) is one of the top low volatility healthcare stocks to buy now. In a report released on July 17, ...

The U.S. FDA ban on compounded versions of Novo Nordisk's Wegovy has increased its prescriptions by 33%. Despite this, ...

One in eight Americans use GLP-1 weight-loss drugs, but are they getting the real thing? Novo Nordisk's dramatic exit from a ...

Current health news covers Roche's Alzheimer's drug research, UnitedHealth's leadership hopes, Nordic Capital's ...

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

Novo Nordisk ( NVO 1.34%) and Regeneron Pharmaceuticals ( REGN -0.27%), two leading drugmakers, have underperformed for most ...

Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...

The Delaware court ruled that Viatris’ drug does not infringe the "administered without another therapeutic agent" limitation ...

As of 2024, Brazil's Semaglutide market was estimated at $581 million. The global market size for the GLP-1 (glucagon-like ...